Gastroenterologia y hepatologia · 2026
Population-based real-world adoption of advanced therapies for ulcerative colitis in Brazil: Trends and regional differences from a nationwide public healthcare database.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gimenez Villamil Maria Paz, Bein Maria Victoria, Valverde Douglas Andreas, Savio Mariane Christina, Araújo Molteni Moretti Rafaela, Proença de Moraes Thyago, Quaresma Abel Botelho, Kotze Paulo Gustavo
Аннотация
OBJECTIVES: To evaluate temporal trends and regional differences in the use of advanced therapies for ulcerative colitis (UC) within Brazil's public healthcare system.
PATIENTS AND METHODS: Retrospective population-based study using Brazilian Department of Informatics of the Unified Health System (DATASUS) data (2019-2023). Patients with an ICD-10 code for UC were included. Monthly dispensing rates of infliximab, vedolizumab, and tofacitinib were analyzed.
RESULTS: By 2023, 195,807 UC patients were identified. Administrative prevalence increased from 26.37 to 62.47 per 100,000 inhabitants. Nationwide use of advanced therapies rose significantly. Vedolizumab showed the highest Annual Average Percent Change (AAPC) (+8.5%), followed by tofacitinib (+4.8%) and infliximab (+1.02%). The Southeast demonstrated the greatest growth, whereas the Northeast showed a significant decline across all therapies.
CONCLUSION: UC prevalence increased markedly in Brazil, with persistent regional disparities in advanced therapy use.
PATIENTS AND METHODS: Retrospective population-based study using Brazilian Department of Informatics of the Unified Health System (DATASUS) data (2019-2023). Patients with an ICD-10 code for UC were included. Monthly dispensing rates of infliximab, vedolizumab, and tofacitinib were analyzed.
RESULTS: By 2023, 195,807 UC patients were identified. Administrative prevalence increased from 26.37 to 62.47 per 100,000 inhabitants. Nationwide use of advanced therapies rose significantly. Vedolizumab showed the highest Annual Average Percent Change (AAPC) (+8.5%), followed by tofacitinib (+4.8%) and infliximab (+1.02%). The Southeast demonstrated the greatest growth, whereas the Northeast showed a significant decline across all therapies.
CONCLUSION: UC prevalence increased markedly in Brazil, with persistent regional disparities in advanced therapy use.